By Pete Evich, AAHP Government Affairs   On Jan. 20, Joe Biden was sworn in as the 46th President of the United States. On the same day, both of Georgia’s newly elected Democratic Senators were also sworn into the U.S. Senate. These events put the Democrats in control of both readm more…

Read More

By Mark Land, AAHP President I have been interested in the application of Real-World Data (RWD) and Real-World Evidence (RWE) for some time now. Originally, I confused RWD and RWE with Patient Centered Data (PCD). In doing so, I thought that patient-supplied evaluation, such as Quality of Life, Compliance, and readm more…

Read More

Consistent, effective, high-quality homeopathic products. That’s what our consumers want in each and every dose. Yet quality doesn’t happen by accident. Manufacturers must create it through process validation. Each manufacturer must ask themselves: Do I have scientific evidence that my (manufacturing) process is capable of reliably delivering quality product?   readm more…

Read More

On March 27, President Trump signed into law the Coronavirus Aid Relief and Economic Security (CARES) Act (HR 748). This landmark legislation provides financial relief for workers, small businesses, and healthcare professionals affected by the coronavirus…

Read More

By Mark Land, AAHP President This year marks the fifth year in a cycle of regulatory review of homeopathic drug product labeling, safety, and quality. AAHP has been there for the industry as an advocate and representative over the entire duration. In 2019 AAHP provided direction and regulatory thought-leadership within readm more…

Read More

Senate Hearing Set for Nov. 20 By Pete Evich, AAHP Govt. Relations   On Nov. 1, President Trump nominated Stephen Hahn, chief medical executive of the MD Anderson Cancer Center in Houston, to be the next U.S. Food and Drug Administration (FDA) commissioner. If confirmed by the Senate, a process readm more…

Read More

By Mark Land, AAHP President It can take several years for manufacturers to implement new guidelines from the Food and Drug Administration (FDA)—and that means they could be at risk in the meantime. However, manufacturers can “get ahead of the game” by monitoring FDA’s guidance development agenda. FDA’s authority to readm more…

Read More